Publication

Engineered type 2 cytokine signalling to improve car-t cell effector functions

2025

Abstract

The invention relates to chimeric antigen receptor constructs and their use for treatments and therapies. Further disclosed are methods of treating and/or preventing a disease, such as e.g. a cancer, an infectious disease, an inflammatory or inflammation-induced disease, a chronic disease or an autoimmune disease.

Official source

Graph Chat

Chat with Graph Search

Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.

DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.

Engineered type 2 cytokine signalling to improve car-t cell effector functions

Chat with Graph Search

Metabolic reinvigoration of NK cells by IL-21 enhances immunotherapy against MHC class I-deficient solid tumors

An integrative approach for studying immunological variation in an aging population – The Milieu Intérieur follow-up study

Designed allosteric biosensors for engineered T cell therapy of cancer